☰
✕

Middle east and asia pacific antibody drugs market

Middle East and Asia Pacific Antibody Drugs Market, by Type (Monoclonal Antibodies, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody), by Disease Indication (Oncology, Neurology, Autoimmune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Middle East (Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East) and Asia Pacific (South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific)) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample
  • Mar 2022
  • CMI4952
  • 242 Pages
  • Excel & Pdf
  • Pharmaceutical

Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. Monoclonal Antibody are a type of antibody made in the laboratory that can be used in the diagnosis or treatment of diseases. In cancer treatment, Monoclonal Antibody may kill cancer cells directly, block the development of tumor blood vessels, or help the immune system kill cancer cells.

The high prevalence of chronic diseases such as cancer, multiple sclerosis, and others and a strong focus of market players on strategic collaborations are the major factors driving the Middle East and Asia Pacific antibody drugs market growth. For instance, in November 2021, CStone Pharmaceuticals, a leading biopharmaceutical company, focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company engaged in the research, development, manufacturing and sales of healthcare products, announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region

The Middle East and Asia Pacific antibody drugs market is estimated to be valued at US$ 43,558.2 Million in 2022 and expected to reach US$ 113,656.9 Million by 2030, witnessing a CAGR of 12.7% over the forecast period (2022-2030).

Figure 1. Middle East and Asia Pacific Antibody Drugs Market Share (%), By Region, 2022

The high prevalence of chronic diseases such as cancer, multiple sclerosis, and others is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period.

The high prevalence of chronic diseases such as cancer multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and others in the Middle East and Asia Pacific region is expected to be the major factor driving the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period. For instance, according to an article published by the Journal of Orthopaedic Surgery and Research in August 2020, the age-standardized prevalence of Rheumatoid Arthritis (RA) in the Tibet Autonomous Region (China) in 2020 was estimated to be 6.30%, wherein the prevalence of RA in women was 2.46% and in men was 9.59%.

Middle East and Asia Pacific Antibody Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 43,558.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 12.7% 2030 Value Projection: US$ 113,656.9 Mn
Geographies covered:
  • Middle East: Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East
  • Asia Pacific: South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific
Segments covered:
  • By Type: Monoclonal Antibody, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, Anti-idiotype Antibody
  • By Disease Indication: Oncology, Neurology, Autoimmune Disorders, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.
Growth Drivers:
  • High prevalence of chronic diseases such as cancer, multiple sclerosis, and others
  • Growing focus of market players on strategic collaborations
Restraints & Challenges:
  • Adverse effects associated with the use of antibody drugs

Figure 2. Middle East and Asia Pacific Antibody Drugs Market Share (%) Analysis, By Disease Indication, 2022

Strong focus of key players on developing novel antibody drugs is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period.

Bispecific antibodies are artificial proteins that have promising applications in the field of cancer immunotherapy. They are comprised of two Monoclonal Antibody held together by a flexible peptide linker. Key companies operating in the market are focusing on developing bispecific antibody drugs, which is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period. For instance, in December 2021, Janssen Pharmaceutical Companies of Johnson & Johnson (researches, develops, manufactures, and sells pharmaceutical products, medical devices and consumer products)announced updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab. Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.

Middle East and Asia Pacific Antibody Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The private healthcare sector is one of the sectors which is majorly impacted by the COVID-19 pandemic. The lockdown or shutdown was imposed in various countries which had a negative impact on the economy of the private healthcare sector in the Middle East and Asia Pacific. This lockdown resulted in the closure of industrial establishments, except the manufacturing of essential commodities, and disruption in the supply chain of products. Supply chain and manufacturing activities in countries in the Middle East and Asia Pacific, such as India, China, United Arab Emirates, and others have been disrupted due to the lockdown.

Moreover, countries such as Thailand, Indonesia, Singapore, and others are facing problems with the transportation of raw materials. For instance, according to data published by the Organization for Economic Co-operation and Development (OECD) in November 2020, the COVID-19 has posed major challenges to the healthcare infrastructure in the Middle East region. Some countries including Lebanon have been severely impacted with regard to the overall management of the COVID-19 crisis. Moreover, the OECD stated that countries such as Iran, Syria, Iraq, the Palestinian Authority, and Yemen faced a lack of hospital beds and low COVID-19 testing capacities.

Middle East and Asia Pacific Antibody Drugs Market: Restraint

Adverse effects associated with the use of antibody drugs are expected to act as a restraint for the Middle East and Asia Pacific antibody drugs market growth over the forecast period. According to an article published by the Frontiers in Immunology journal in June 2018, some of the common side effects associated with the use of immunoglobulin therapy (antibody drugs), including headache, flushing, malaise, chills, fever, fatigue, and lethargy, are transient and mild. However, immunoglobulin therapy may also cause adverse effects such as aseptic meningitis, renal impairment, arrhythmia, thrombosis, hemolytic anemia, transfusion-related acute lung injury (TRALI), and others.

Key Players

Major players operating in the Middle East and Asia Pacific antibody drugs market include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Type
      • Market Snapshot, By Disease Indication
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. Middle East and Asia Pacific Antibody Drugs Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Market Trends
    • Product Launches
    • Key Developments
    • Regulatory Scenario
    • Government Initiatives
    • Overview of Clinical and Commercial Manufacturing of Therapeutic Antibody Drugs
    • Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation
    • Collaborations & Agreements
    • Epidemiology
    • PEST Analysis
  4. Middle East and Asia Pacific Antibody Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Government Initiative to Combat COVID-19
    • Overall Impact
  5. Middle East and Asia Pacific Antibody Drugs Market, By Type, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Monoclonal Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Polyclonal Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Bispecific Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Biosimilars
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Single Domain Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • CAR-T
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Anti-idiotype Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  6. Middle East and Asia Pacific Antibody Drugs Market, By Disease Indication, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Neurology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Autoimmune Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  7. Middle East and Asia Pacific Antibody Drugs Market, By Distribution Channel, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  8. Middle East and Asia Pacific Antibody Drugs Market, By Region, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Region at Trends
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • Kingdom of Saudi Arabia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • UAE
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Israel
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Iran
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Jordan
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Turkey
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Qatar
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Rest of Middle East
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • South East Asia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • The Philippines
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Malaysia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Singapore
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Thailand
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Vietnam
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Rest of South East Asia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Taiwan
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Hong Kong
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Macau
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Japan
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • South Korea
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • India
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Australia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • China
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
        • Rest of Asia Pacific
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 – 2030, (US$ Million)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Million)
  9. Competitive Snapshot
    • Company Profiles
      • Novartis AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Amgen, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Hoffmann-La Roche Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Johnson & Johnson Private Limited
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AbbVie
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Eli Lilly and Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • GlaxoSmithKline plc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Daiichi Sankyo Company, Limited
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Celltrion Healthcare Co., Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Mylan N.V.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Boehringer Ingelheim International GmbH.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Biocon
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Merck & Co., Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 88 market data tables and 47 figures on "Middle East and Asia Pacific Antibody Drugs Market” - forecast to 2030

Detailed Segmentation:

  • Middle East and Asia Pacific Antibody Drugs Market, By Type:
    • Monoclonal Antibody
    • Polyclonal Antibody
    • Bispecific Antibody
    • Biosimilars
    • Single Domain Antibody
    • CAR-T
    • Anti-idiotype Antibody
  • Middle East and Asia Pacific Antibody Drugs Market, By Disease Indication:
    • Oncology
    • Neurology
    • Autoimmune Disorders
    • Others
  • Middle East and Asia Pacific Antibody Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Middle East and Asia Pacific Antibody Drugs Market, By Region:     
    • Middle East
      • By Type
        • Monoclonal Antibody
        • Polyclonal Antibody
        • Bispecific Antibody
        • Biosimilars
        • Single Domain Antibody
        • CAR-T
        • Anti-idiotype Antibody
      • By Disease Indication
        • Oncology
        • Neurology
        • Autoimmune Disorders
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Kingdom of Saudi Arabia
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • UAE
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Israel
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Iran
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Jordan
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Turkey
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Qatar
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Middle East
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Asia Pacific
      • By Type
        • Monoclonal Antibody
        • Polyclonal Antibody
        • Bispecific Antibody
        • Biosimilars
        • Single Domain Antibody
        • CAR-T
        • Anti-idiotype Antibody
      • By Disease Indication
        • Oncology
        • Neurology
        • Autoimmune Disorders
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South East Asia
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • The Philippines
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Malaysia
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Singapore
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Thailand
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Vietnam
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of South East Asia
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Taiwan
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Hong Kong
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Macau
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Japan
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • South Korea
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • India
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Australia
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • China
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Asia Pacific
          • By Type
            • Monoclonal Antibody
            • Polyclonal Antibody
            • Bispecific Antibody
            • Biosimilars
            • Single Domain Antibody
            • CAR-T
            • Anti-idiotype Antibody
          • By Disease Indication
            • Oncology
            • Neurology
            • Autoimmune Disorders
            • Others
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the Middle East and Asia Pacific antibody drugs market during the forecast period (2022-2030)?

The Middle East and Asia Pacific antibody drugs market size is estimated to be valued at US$ 43,558.2 Million in 2022 and expected to exhibit a CAGR of 12.7% between 2022 and 2030.

What are the major factors driving the market growth?

The high prevalence of chronic diseases such as cancer, multiple sclerosis, and others and a strong focus of market players on strategic collaborations are major factors driving the market growth.

Which is the major type segment in the market?

Monoclonal Antibody is the major type segment in the market.

What are the key factors hampering growth of the market?

Adverse effects associated with the use of antibody drugs are the major factors restraining the growth of the market.

Which are the major players operating in the market?

Major players operating in the market include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now